logo
Plus   Neg
Share
Email

Genentech Reports Positive Topline Data From Xolair Phase III Studies

Genentech, a member of the Roche Group (RHHBY), said Omalizumab has met both co-primary endpoints and key secondary endpoints across both POLYP 1 and POLYP 2 phase III trials for the treatment of adults with chronic rhinosinusitis with nasal polyps (CRSwNP) who have not adequately responded to intranasal corticosteroids. Xolair (Omalizumab) significantly reduced nasal polyps and congestion symptoms in adults with chronic rhinosinusitis with nasal polyps in both studies. Xolair was well tolerated and the safety profile was consistent with the previous trials.

In the US., Novartis and Genentech, Inc. jointly develop and co-promote Xolair. Outside the US, Novartis markets Xolair and records its sales. The companies plan to discuss the results with the FDA.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The United Auto Workers union on Sunday called for a strike at General Motors at midnight after both the parties failed to reach a tentative deal before a Saturday deadline. The last time the union declared a strike at GM was in 2007. General Motors has detailed its most recent offer, including 5,400 jobs and $7 billion in investment at its US plants. The United Auto Workers union reportedly plans to go on strike against auto giant General Motors Co. (GM) after both the parties failed to reach a tentative deal before a Saturday deadline. According to CNBC, the strike has been called despite GM saying it presented a "strong offer" to the union.... Millennials and Generation Zs, or people aged between 18 to 34 year, pay more for car repairs, according to a new survey. The average American spent $1,986 over the past five years on vehicle repairs and maintenance, according to a survey by Ally Financial conducted by Harris Poll. However, among...
Follow RTT